A carregar cotações...
Previsão
| Comprar |
1 |
| Manter |
0 |
| Vender |
0 |
Notícias Ir para o feed de notícias
Protagenic Therapeutics reports sharply improved EPS for Q4 2025
Protagenic Therapeutics released results for the quarter ended 31.12.2025 and reported earnings per share (EPS) of 1.14 USD. In the same quarter a year earlier EPS was -3.360 USD, so the company recorded a marked improvement. » Mais em finanzen.net
Protagenic Therapeutics appoints William Nichols Jr. as president
Protagenic Therapeutics has appointed William (Bill) Nichols Jr., effective February 3, 2026, as president. Nichols (51) joins from senior commercial roles at bluebird bio, Dova Pharmaceuticals and Bristol-Myers Squibb. His contract provides a base salary of USD 350,000, an annual target bonus of 40% and stock options amounting to about 1.0% of the fully diluted shares. » Mais em de.investing.com
Protagenic Therapeutics reports quarterly loss of $0.47 per share
Protagenic Therapeutics published on 26.11.2025 the figures for the quarter ended 30.09.2025 and reported a loss per share of $0.47. In the same quarter last year, earnings per share were -$1.96. No further financial details were reported. » Mais em finanzen.net
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | junho de 2026 | |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | -7,28 mil | 31,71% |
| Ganho líquido | -844,33 mil | 80,32% |
| EBITDA | -834,97 mil | 79,52% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 1,4 mi |
Número de ações | 1,81 mi |
Máximo/mínimo de 52 semanas | € 3,92 - € 0,11 |
| Dividendos | Não |
Beta | 1,07 |
PER (PE Ratio) | 0,31 |
PEG (PEG Ratio) | 0,00 |
P/VC (PB Ratio) | 0,95 |
P/V (PS Ratio) | 0,00 |
Perfil da empresa
Protagenic Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entdeckung und Entwicklung von Therapeutika zur Behandlung stressbedingter neuropsychiatrischer und stimmungsbezogener Störungen befasst. Die Leitsubstanz ist PT00114, eine synthetische Form von Teneurin carboxy-terminal associated peptide, einem endogenen Signalpeptid des Gehirns, das überaktive Stressreaktionen dämpfen kann. Das Unternehmen hat seinen Sitz in New York, New York.
| Nome | Protagenic Therapeutics Aktie |
| CEO | Garo H. Armen |
| Sede | New York,
ny EUA |
| Site | |
| Setor | Indústria |
| Indústria | Serviços comerciais e fornecimentos |
| Entrada em bolsa | 27/04/2021 |
| Colaboradores | 2 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | PTIX |
Frankfurt | MBPC.F |
München | MBPC.MU |
